AzurRx BioPharma reports positive results in its Phase 2a trial of pancreatitis drug
- Admin
- Jul 16, 2018
- 1 min read
MS1819-SD was developed to treat exocrine pancreatic insufficiency caused by chronic pancreatitis
AzurRx BioPharma Inc (NASDAQ:AZRX) announced a successful Phase 2a trial study of its pancreatitis drug.
MS1819-SD is designed to treat exocrine pancreatic insufficiency caused by chronic pancreatitis, a disease characterized by inflammation of the pancreas.
Initial data from the study shows a “very strong safety and efficacy profile”, according to the company’s press statement.
The Brooklyn-based biopharma will look into applying the drug to the treatment of cystic fibrosis as well.
“Based on these data, we believe we have the basis for initiating a Phase IIb trial of MS1819 in cystic fibrosis patients in the fall of 2018,” said Chief Medical Officer James Pennington in a statement.
The biopharma specializes in the development of non-systemic, recombinant therapies for gastrointestinal diseases. While MS1819 is its lead drug candidate, it is also conducting early-stage research into the prevention of hospital-acquired infections.
Shares jumped nearly 8% to US$3.16 in Friday morning trading.
Recent Posts
See All
Meet Sara from Iraq, a courageous mother fighting an uphill battle to ensure her daughter, Rozhin, receives the care she desperately...
Tunisia is home to about 250 people with cystic fibrosis (CF), which was first discovered in 1994. Tunisia's population is approximately...
Comments